2025 年限制性股票激励计划首次授予结果公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、限制性股票授予结果 （一）实际授予基本情况 （二）实际授予明细表 | 姓 名 | 职 务 | 获授的限制 性股票数量 （股） | 获授的限制性股 票数量占授予限 制性股票总量的 | 实际授予数量 占激励计划公 告日总股本的 | | --- | --- | --- | --- | --- | | | | | 比例（%） | 比例（%） | | 一、董事、高级管理人员 | | | | | | 王敏 | 董事 | 60,000 | 4.14% | 0.06% | | 王芳 | 董事、高级管 理人员 | 60,000 | 4.14% | 0.06% | | 彭月初 | 董事、高级管 | 70,000 | 4.83% | 0.07% | | | 理人员 | | | | | 熊志辉 | 董事 | 100,000 | 6.90% | 0.10% | | 段皓龄 | 高级管理人员 | 70,000 | 4.83% | 0. ...

Group 1 - The core transaction on August 4 involved 150,000 shares of JinHao Medical, with a total transaction value of 3.576 million yuan, at a price of 23.84 yuan per share, representing a discount of 3.48% compared to the closing price of the day [2][3] - Over the past month, JinHao Medical has recorded a total of 5 block trades, amounting to 15.7545 million yuan [3] - The closing price of JinHao Medical on the day of the transaction was 24.70 yuan, reflecting a decline of 2.72%, with a trading volume of 6.38525 million yuan and a turnover rate of 4.66% [3] Group 2 - The buyer of the block trade was CITIC Securities Co., Ltd. Beijing Hujialou Securities Business Department, while the seller was GF Securities Co., Ltd. Huizhou Xiapu Road Securities Business Department [2][3] - The stock has seen a cumulative increase of 0.61% over the past five days [3]

Group 1 - The core transaction involved JinHao Medical, with a large block trade executed at a price of 23.84 yuan per share, totaling 150,000 shares and an amount of 3.576 million yuan [1] - The buying brokerage was CITIC Securities Co., Ltd., Beijing Hujialou Securities Branch, while the selling brokerage was GF Securities Co., Ltd., Huizhou Xiapu Road Branch [1] - JinHao Medical specializes in the research, production, and sales of rehabilitation and home medical devices, including hearing aids, nebulizers, air mattresses, and chips [1] Group 2 - The company has received national-level recognition as a "specialized, refined, characteristic, and innovative" enterprise [1] - JinHao Medical holds a total of 134 patents, including 121 in China and 13 in the United States, with 22 invention patents, 13 software copyrights, and 1 integrated circuit layout design [1] - The company has recently obtained EU MDR certification, which expands its access to high-end market qualifications [1]

Group 1 - The stock of JinHao Medical experienced a block trade on August 4, with a transaction price of 23.84 yuan, representing a discount of 3.48% compared to the closing price of the same day [1] - A total of 150,000 shares were traded in this block transaction, amounting to 3.576 million yuan, with the buyer being CITIC Securities and the seller being GF Securities [1] - Over the past three months, there have been 8 block trades for this stock, totaling 11,500 hands, all executed at a discount [1] Group 2 - As of August 4, 2025, JinHao Medical's stock closed at 24.7 yuan, down 2.72%, with a turnover rate of 4.66% and a trading volume of 25,700 hands, amounting to 63.8525 million yuan [1] - In the past six months, there has been a net reduction of 1,072,400 shares held by shareholders, with specific details of shareholding changes provided [1] - No institutional ratings have been reported for this stock in the last 90 days [2]

Group 1: Market Performance - The average daily change for the North Exchange (北证) and A-shares (A股) shows significant fluctuations, with a peak of 30% for Tianrun Technology (天润科技) on July 25, 2025[8] - The trading volume for the North Exchange reached a total of 600 billion CNY, with an average turnover rate of 16% as of July 25, 2025[6] - The average price-to-earnings ratio (PE) for companies listed on the North Exchange varies significantly across industries, with some sectors showing a PE as high as 516.07[12] Group 2: Stock Performance - The top-performing stocks on July 25, 2025, include Tianrun Technology with a 30% increase and a market capitalization of 29.19 billion CNY[8] - Conversely, the worst-performing stock, Jikang Technology (基康技术), saw a decline of 12.56% with a market capitalization of 52.76 billion CNY[9] - The average daily change for the North Exchange was notably higher than that of the A-share market, indicating a more volatile trading environment[7] Group 3: Risks and Challenges - The report highlights risks including lower-than-expected policy support, insufficient technological innovation, and increased market competition[13] - Market volatility remains a significant concern, impacting investor sentiment and stock performance across various sectors[13]

Core Viewpoint - The cross-border e-commerce sector experienced a slight increase of 0.62% on July 25, with a total capital inflow of 10.46 million [1] Group 1: Market Performance - A total of 92 stocks in the sector rose, while 62 stocks declined [1] - The top-performing stocks included: - InSail Group with a rise of 19.99% - Easy Point World with a rise of 6.38% - JinHao Medical with a rise of 6.23% [1][1][1] Group 2: Capital Flow - The leading stocks by net capital inflow were: - InSail Group with a net inflow of 208 million - BlueFocus Communication Group with a net inflow of 247 million - JinHao Medical with a net inflow of 676.31 thousand [1][1][1] Group 3: Declining Stocks - The stocks with the largest declines included: - LiShang GuoChao with a drop of 5.95% - SanYang Ma with a drop of 5.22% - HaiQi Group with a drop of 3.79% [1][1][1]

Group 1 - The A-share medical device sector is experiencing a strong rebound, with companies such as Zhengchuan Co. and Kangtai Medical hitting the daily limit, while Nanwei Medical has surged over 10% [1] - Other companies in the sector, including Lude Medical, Shandong Pharmaceutical Glass, Anjisi, Jinhao Medical, and Maipu Medical, are also seeing gains [1] - The National Healthcare Security Administration has announced encouragement for drug research and innovation, supporting the global expansion of China's innovative drugs and medical devices [1]

Core Viewpoint - The medical device industry experienced a slight decline of 0.02% on July 23, with a total capital inflow of 23.87 million [1] Group 1: Market Performance - A total of 49 stocks in the sector rose, while 71 stocks fell [1] - The top ten decliners included: - JinHao Medical (-6.2%) - WeiSi Medical (-6.18%) - BeiYiKang (-5.91%) - Rejing Biology (-5.1%) - AiPeng Medical (-3.78%) - DiRui Medical (-3.55%) - YingKe Medical (-2.78%) - AiWei Technology (-2.58%) - YiRui Technology (-2.46%) - KangTuo Medical (-2.35%) [1] Group 2: Capital Flow - The net capital outflow for the top decliners included: - JinHao Medical: -15.52 million - WeiSi Medical: -13.50 million - BeiYiKang: -9.36 million - Rejing Biology: -14.75 million - AiPeng Medical: -15.57 million [1] Group 3: Top Gainers - The top gainers in the sector included: - OuPuKangShi (14.13%) - TouJing Life (5.7%) - KangZhong Medical (5.07%) - TianYi Medical (4.97%) - AoTai Biology (3.52%) [1]

证券代码：872925 证券简称：锦好医疗 公告编号：2025-066 惠州市锦好医疗科技股份有限公司 关于调整 2025 年限制性股票激励计划激励对象名单及 授予价格的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2025 年 7 月 11 日召开第 三届董事会第十二次会议，审议通过了《关于调整 2025 年限制性股票激励计划激励对 象名单及授予价格的议案》，对公司 2025 年限制性股票激励计划（以下简称"本次激励 计划"）激励对象名单和授予价格进行调整，现将相关内容公告如下： 一、本次激励计划已履行的相关审批程序 1、2025 年 5 月 12 日，惠州市锦好医疗科技股份有限公司（以下简称"公司"）召 开第三届董事会第十一次会议，审议《关于<惠州市锦好医疗科技股份有限公司 2025 年限制性股票激励计划（草案）>的议案》《关于公司 2025 年限制性股票激励计划授 予的激励对象名单的议案》《关于制定<惠州市锦好医疗科技股份有限公司 202 ...

一、审议及表决情况 （一）本次权益授予已履行的决策程序和信息披露情况 1、2025 年 5 月 12 日，惠州市锦好医疗科技股份有限公司（以下简称"公司"）召 开第三届董事会第十一次会议，审议《关于<惠州市锦好医疗科技股份有限公司 2025 年限制性股票激励计划（草案）>的议案》《关于公司 2025 年限制性股票激励计划授 予的激励对象名单的议案》《关于制定<惠州市锦好医疗科技股份有限公司 2025 年限 制性股票激励计划实施考核管理办法>的议案》《关于与激励对象签署<限制性股票激 励计划限制性股票授予协议>的议案》，并审议通过《关于拟认定公司核心员工的议 案》《关于提请公司股东会授权董事会办理限制性股票激励相关事宜的议案》等议案。 公司第三届董事会独立董事专门会议第六次会议已审议通过相关议案，并对本次限制 性股票激励计划相关事项出具了审查意见。 证券代码：872925 证券简称：锦好医疗 公告编号：2025-067 惠州市锦好医疗科技股份有限公司 2025 年限制性股票激励计划首次权益授予公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准 ...